An Open Label,Single-center, Non-interventional Prospective Study to Determine the Efficacy of Iron Therapy Using Intravenous Ferric Carboxymaltose and Its Effect in Reducing Arrhythmic Events in Participants With Iron Deficiency and HFrEF
Latest Information Update: 05 Jul 2023
Price :
$35 *
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Arrhythmias; Iron deficiency anaemia
- Focus Pharmacodynamics
- 29 Jul 2021 New trial record